Roche files BLA for breakthrough T-DM1 cancer therapy

Wowed by stellar mid-stage data, Roche has filed a BLA for trastuzumab-DM1, or T-DM1, seeking approval to market the pioneering conjugated monoclonal antibody to women with treatment-resistant HER2 positive breast cancer. For Roche, T-DM1 represents a potential mega-blockbuster capable of eventually rivaling Herceptin in the market for cancer drugs. And the filing marks a major milestone for the investigators at Genentech and Immunogen who successfully combined a monoclonal antibody with a...